Pacira | PCRX - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Assertio Holdings USD -2.88M 648K 2024-09
Astellas Pharma JPY 133.96B 29.77B 2025-12
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Cara Therapeutics USD -4.91M 3.17M 2025-03
Coherus Biosciences USD -46.35M 90.86M 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
J&J USD 4.97B 2.53B 2025-12
Ligand Pharmaceuticals USD 141.14M 102M 2025-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Novo Nordisk DKK 33.8B 3.23B 2025-06
Omeros USD -65.12M 21.27M 2024-06
Pacira USD 9.52M 11.45M 2025-09
Perrigo USD 22.4M 19.2M 2025-09
Pfizer USD 3.33B 290M 2025-09
Supernus Pharmaceuticals USD -1.91M 56.04M 2025-12
Teva Pharmaceutical Industries USD 91M 555M 2025-12
Xeris Pharmaceuticals USD 11.08M 10.46M 2025-12
Xoma USD 15.98M 24.58M 2024-06
Zoetis USD 887M 15M 2025-09